| Literature DB >> 33117723 |
Kathryn Fisher1,2, Maureen Markle-Reid1,2,3, Jenny Ploeg1,2,4, Amy Bartholomew1, Lauren E Griffith3, Amiram Gafni3,5, Lehana Thabane3, Marie-Lee Yous1,2.
Abstract
BACKGROUND: Multimorbidity, the co-existence of 2+ (or 3+) chronic diseases in an individual, is an increasingly common global phenomenon leading to reduced quality of life and functional status, and higher healthcare service use and mortality. There is an urgent need to develop and test new models of care that incorporate the components of multimorbidity interventions recommended by international organizations, including care coordination, interdisciplinary teams, and care plans developed with patients that are tailored to their needs and preferences.Entities:
Keywords: Multimorbidity; community-based care; home care services; older adults; pragmatic randomized controlled trial; self-management
Year: 2020 PMID: 33117723 PMCID: PMC7573753 DOI: 10.1177/2235042X20963390
Source DB: PubMed Journal: J Comorb ISSN: 2235-042X
Multimorbidity intervention versus usual home care services.
|
|
|
|
|---|---|---|
| Team-based care | Dedicated interprofessional (IP) teams of home care providers (Care Coordinator, Registered Nurse, Physiotherapist, Occupational Therapist, Personal Support Worker). Home care providers received training in best practices for the prevention and management of multimorbidity, team-based care, strengths-based practice, strategies to promote self-management, patient-centered care, and caregiver assessment and support strategies. | No dedicated IP teams. |
| Patient- and family-centered care | Providers use a patient-as-partner approach, where they work alongside patients and their family caregivers to set goals that informed an individualized care plan that is tailored to patient needs and preferences. | Care is often provider-centered rather than patient-centered. |
| Team communication and collaboration | Monthly IP case conferences to discuss patient goals and plan of care over 6-month intervention period. | Case conferences occur on an ad hoc basis with selected home care providers. |
| Personal support worker involvement in the team | Personal support workers are full members of the IP team and received training in multimorbidity, team-based care, and strengths-based practice. The Observe, Coach, Assist, and Report (OCAR) framework was used to enhance IP collaboration that is inclusive of the PSW.[ | Personal support workers are not formally integrated into IP home care teams. |
| Prevention and management of multimorbidity | Focus of the intervention is on the prevention and management of multimorbidity, care coordination to support their multiple chronic conditions, and a holistic, long-term approach to care planning. This includes regular screening and assessment of multimorbidity risk factors using validated tools. This also includes consideration of broader determinants of health (e.g., lifestyle, social and economic factors). | Most home care interventions focus on the management of single diseases. Moreover, with scarce resources, home care is increasingly focused on acute, short-term medical needs. |
| Support for Self-Management | Use of a strengths-based approach to promote self-management and behavioral change. Provision of monthly in-home visits by IP team over 6-month intervention period. | With scarce resources, home care is increasingly focused on acute, short-term medical needs versus a long-term approach focused on prevention, health promotion. |
| Support for family caregivers | Focus of the intervention is on both patients and their family caregivers. Caregiver assessment and support was an integral component of the intervention. | Eligibility for home care services is based on patient’s functional/medical needs, not the needs of family caregivers. Screening of family caregivers for caregiver distress and the provision of support and health promotion services for caregivers is not a part of routine home care practice. |
| Collaboration with primary care physician | Formal mechanisms for communication with the patient’s primary care physician using medication, dementia, delirium, and depression alerts. | No formal mechanism for communication between home care providers and primary care physician. |
| Care Coordination | Care Coordinator role expanded to include leading the IP team, ongoing case management and facilitate access to health and social services over the 6-month intervention period. | Care coordinator role is to assess patient’s eligibility for home care services, arranging and coordinating home care services, provide information and referral to community agencies, and monitor service delivery through in-home assessments with patients. |
Figure 1.Study flow diagram.
Baseline characteristics of trial participants (n = 59).
|
|
|
|
|---|---|---|
| Sex, n (%) | ||
| Female, n (%) | 13 (43) | 16 (55) |
| Male, n (%) | 17 (57) | 13 (45) |
| Age in years, n (%) | ||
| 65–69 | 3 (10) | 2 (7) |
| 70–74 | 8 (27) | 6 (21) |
| 75+ | 19 (63) | 21 (72) |
| Marital Status, n (%) | ||
| Married, living together | 15 (50) | 13 (45) |
| Widowed, divorced, separated | 15 (50) | 16 (55) |
| Annual Income ($CAD), n (%) | ||
| $0 to $39,999 | 15 (50) | 12 (41) |
| $40,000+ | 3 (10) | 3(10) |
| Missing | 12 (40) | 14 (48) |
| Number of chronic conditions, mean (SD) | 8.63 (4.71) | 8.72 (4.33) |
| Top chronic conditions, n (%) | ||
| Cardiovascular | 27 (90) | 27 (93) |
| Kidney & Urogenital | 18 (60) | 16 (55) |
| Arthritis | 17 (57) | 18 (62) |
| Gastrointestinal | 16 (53) | 13 (45) |
| Endocrine (diabetes, thyroid) | 16 (53) | 19 (66) |
| Hearing and Vision | 16 (53) | 20 (69) |
| Number of prescription medications, mean & SD | 7.72 (2.81) | 8.79 (3.45) |
| Fall within last 12 months | ||
| Yes | 16 (53) | 17 (61) |
| No | 14 (47) | 11 (39) |
| HRQoL—Physical Functioninga, mean (SD) | 28.14 (6.67) | 28.74 (11.15) |
| HRQoL—Mental Functioningb, mean (SD) | 45.30 (13.77) | 53.40 (13.46) |
| Depressive Symptomsc, mean & SD | 11.67 (7.77) | 8.07 (5.11) |
| Anxietyd, mean (SD) | 5.90 (6.41) | 2.86 (4.36) |
| Self-Efficacye, mean (SD) | 5.37 (2.81) | 6.53 (2.27) |
a Measured by Physical Component Summary Score (PCS) of SF-12 survey, scale range 0–100.
b Measured by Mental Component Summary Score (MCS) of SF-12 survey, scale range 0–100.
c Measured by Center for Epidemiologic Studies Depression 10-Item Scale (CESD-10), scale range 0–30.
d Measured by Generalized Anxiety Disorder 7-Item Scale (GAD-7), scale range 0–21.
e Measured by Self Efficacy for Managing Chronic Disease 6-Item Scale, scale range 0–10.
Outcomes (baseline, 6 months) and between group differences (results for multiple imputation and complete case).
|
|
| |||
|---|---|---|---|---|
|
|
|
|
|
|
| SF-12: Physical Function | −3.93 (−8.52 to 0.67) | 0.09 | −1.66 (−6.41 to 3.08) | 0.48 |
| Role Physical | −2.87 (−9.46 to 3.72) | 0.38 | −4.50 (−10.22 to 1.22) | 0.12 |
| Bodily Pain | −6.20 (−18.68 to 6.27) | 0.32 | −3.30 (−13.59 to 6.99) | 0.52 |
| General Health | 3.86 (−6.23 to 13.94) | 0.43 | 8.72 (2.30 to 15.14) | 0.01 |
| Vitality | 1.69 (−5.62 to 8.99) | 0.65 | 0.14 (−6.75 to 7.03) | 0.97 |
| Social Function | −4.28 (−15.29 to 6.73) | 0.44 | −8.30 (−18.35 to 1.75) | 0.10 |
| Role Emotion | 5.60 (−4.62 to 15.82) | 0.26 | 4.09 (−3.07 to 11.25) | 0.25 |
| Mental Health | 2.62 (−6.65 to 11.88) | 0.56 | 3.58 (−2.40 to 9.57) | 0.23 |
| PCS | −4.94 (−12.53 to 2.66) | 0.20 | −2.91 (−9.66 to 3.84) | 0.39 |
| MCS | 4.91 (−2.00 to 11.81) | 0.16 | 3.19 (−3.06 to 9.43) | 0.31 |
| CESD-10 | −1.57 (−4.71 to 1.58) | 0.32 | −3.07 (−6.48 to 0.33) | 0.08 |
| GAD-7 | 0.22 (−1.11 to 1.55) | 0.74 | 0.43 (−1.28 to 2.14) | 0.61 |
| Self-Efficacy | −0.13 (−1.06 to 0.81) | 0.79 | 0.26 (−1.04 to 1.57) | 0.68 |
a Intervention mean – control mean. Estimate from ANCOVA model, adjusted for baseline outcome value.
b p Value for t statistic of parameter estimate in ANCOVA model.
c Center for Epidemiologic Studies Depression 10-Item Scale (CESD-10).
d Generalized Anxiety Disorder 7-Item Scale (GAD-7).
e Self efficacy measured using Stanford Self Efficacy for Managing Chronic Disease 6-Item Scale.
Figure 2.(a) Number of participants with hospitalization 6 months prior to baseline vs 6-month intervention period (n = 32 complete cases, 16 in each group). (b) Number hospitalizations 6 months prior to baseline vs 6-month intervention period (n = 32 complete cases, 16 in each group).
Figure 3.(a) Number of participants with ED visits 6 months prior to baseline vs 6-month intervention period (n = 32 complete cases, 16 in each group). (b) Number of ED visits 6 months prior to baseline vs 6-month intervention period (n = 32 complete cases, 16 in each group).
Intervention group comparison of hospitalizations 6 months before baseline versus 6 months after baseline (n = 16 complete cases).a
|
|
|
| |
|---|---|---|---|
|
| 1 | 8 | 9 |
|
| 0 | 7 | 7 |
|
| 1 | 15 | 16 |
a McNemar test showed a significant difference (p value = 0.01, α = 0.05), indicating that the proportion of hospitalizations during the period 6 months prior to baseline (0.56) was significantly higher (statistically) compared to the proportion of hospitalizations during the 6-month intervention period (0.06).
Control group comparison of hospitalizations 6 months before baseline versus 6 months after baseline (n = 16 complete cases).a
|
|
|
| |
|---|---|---|---|
|
| 3 | 7 | 10 |
|
| 1 | 5 | 6 |
|
| 4 | 12 | 16 |
a McNemar test showed no a significant difference (p value = 0.08, α = 0.05), indicating that the proportion of hospitalizations during the period 6 months prior to baseline (0.63) did not significantly differ (statistically) from the proportion of hospitalizations during the 6-month intervention period (0.25).
Intervention group comparison of emergency department visits 6 months before baseline versus 6 month after baseline (n = 16 complete cases).a
|
|
|
| |
|---|---|---|---|
|
| 4 | 6 | 10 |
|
| 2 | 4 | 6 |
|
| 6 | 10 | 16 |
a McNemar test showed no a significant difference (p value = 0.27, α = 0.05), indicating that the proportion of ED visits during the period 6 months prior to baseline (0.63) did not differ significantly (statistically) from the proportion of hospitalizations during the 6-month intervention period (0.38).
Control group comparison of emergency department visits 6 months prior to baseline versus 6 month intervention period (n = 16 complete cases).a
|
|
|
| |
|---|---|---|---|
|
| 3 | 10 | 13 |
|
| 1 | 2 | 3 |
|
| 4 | 12 | 16 |
a McNemar test showed a significant difference (p value = 0.02, α = 0.05), indicating that the proportion of ED visits during the period 6 months prior to baseline (0.81) was significantly higher (statistically) compared to the proportion of ED visits during the 6-month intervention period (0.25).
Comparison of HSSUI costs (6 month costs at baseline vs 6 month intervention period).
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| Family Physician | 270.20 (154.40, 463.20) | 386.00 (198.00, 463.20) | 0.00 (−194.00, 203.05) | 249.00 (229.00, 347.40) | 193.01 (77.20, 386.01) | −77.20 (−124.52, 77.20) | −0.38 (0.71) |
| Physician Specialist | 123.33 (71.65, 204.48) | 56.27 (0.00, 168.74) | −78.35 (−184.04, 18.80) | 73.71 (20.44, 168.56) | 16.05 (0.00, 168.80) | −14.61 (−75.76, 71.65) | 1.21 (0.23) |
| Home Care & Outpatientb | 50.12 (0.00, 105.62) | 1,262.69 (1,001.07, 1,599.73) | 1,121.70 (967.96, 1,456.65) | 43.12 (0.00, 330.62) | 30.62 (0.00, 61.23) | 0.00 (−43.12, 61.23) | −3.00 (0.003) |
| Ambulance & 911 | 0.00 (0.00, 264.80) | 0.00 (0.00, 132.40) | 0.00 (−120.00, 0.00) | 240.00 (0.00, 372.40) | 0.00 (0.00, 120.00) | 0.00 (−372.40, 0.00) | −0.34 (0.73) |
| Emergency Department | 239.31 (0.00, 478.62) | 0.00 (0.00, 239.31) | −119.66 (−239.31, 0.00) | 239.31 (239.31, 478.62) | 0.00 (0.00, 119.66) | −239.31 (−478.62, 0.00) | −1.13 (0.26) |
| Hospital | 8,629.50 (0.00, 23,535.00) | 0.00 (0.00, 0.00) | −7,845.00 (−21,966.00, 0.00) | 7,845.00 (0.00, 32.949.00) | 0.00 (0.00, 784.50) | −6,276.00 (−23.535.00, 0.00) | 0.21 (0.83) |
| Equipment | 0.00 (0.00, 191.13) | 0.00 (0.00, 110.00) | 0.00 (−83.48, 0.00) | 92.50 (0.00, 209.00) | 0.00 (0.00, 22.50) | −57.50 (−160.00, 0.00) | −1.16 (0.25) |
| Prescription Meds | 693.72 (506.65, 1,063.99) | 807.12 (275.81, 1,258.93) | 2.61 (−183.32, 282.32) | 908.78 (405.89, 1,404.53) | 658.68 (305.76, 936.39) | −145.01 (−813.36, 31.44) | −1.71 (0.09) |
| Recreational Services | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | −1.68 (0.09) |
| Transportation | 0.00 (0.00, 42.00) | 0.00 (0.00, 4.00) | 0.00 (−18.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 1.07 (0.29) |
| Total Costs | 12,448.91 (1,521.59, 27,083.52) | 2,998.23 (2,278.48, 3,441.14) | −7,361.41 (−20,964.54, 1,180.02) | 9,722.88 (2,569.41, 36,857.12) | 1,914.33 (789.62, 6,325.88) | −4,364.80 (−21,596.58, −65.66) | −0.28 (0.78) |
aWilcoxon-Mann-Whitney test is a non-parametric analog to the independent samples t-test. The hypothesis being tested is whether the two medians are equal.
b Includes the costs of the intervention for the intervention group (in-home visits, monthly case conferences).
c A positive median cost difference indicates that median costs were higher at 6 months. A negative median cost difference indicates that median costs were lower at 6 months.